Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ikaria’s respiratory gas to receive Japanese approval
INOflo (brandname INOmax in the US) will be indicated for the treatment of newborns who suffer from hypoxic respiratory failure, a potentially life-threatening condition that keeps babies’ lungs
INOflo (brandname INOmax in the US) will be indicated for the treatment of newborns who suffer from hypoxic respiratory failure, a potentially life-threatening condition that keeps babies’ lungs
Franck Grimaud, CEO of Vivalis, said: “This new license confirms again that the EBx cell platform is a reference cell substrate for the industrial manufacture of viral vaccines.
The joint venture (JV) will provide a range of services in drug discovery research for international companies and research organizations seeking to develop and market pharmaceutical products and
This trial demonstrates PL 2100 Aspirin-PC may bridge to the safety and efficacy of aspirin for prescription (Rx) treatment and prevention of secondary prevention of stroke and myocardial
Invivodata designed a DiaryPRO solution for over 1,000 international trial subjects to use and over 90 investigative sites to administer. During the trial, investigative sites across the US,
Of the 45 patients enrolled in this study, 16 patients from four European centers have completed two years of Rheos hypertension (HT) therapy. Blood pressure measurements were taken
A total of 35 subjects, of whom 29 received BTT-1023, were enrolled into the placebo-controlled study. BTT-1023 was generally well tolerated and no serious adverse events were reported
Under the terms of the agreement, Merck will provide Nuevolution with an upfront payment, research funding and milestone payments as candidate molecules progress through preclinical and clinical development
The offer price represents a 14.6% premium to Zentiva’s April 30, 2008 closing price of CZK916 the last day before PPF Group made an announcement of its intended
The first-line Indolent trial (FIT), which evaluated the use of Zevalin as first-line consolidation therapy in follicular lymphoma patients, was sponsored by Bayer Schering Pharma, which has exclusive